Aquestive therapeutics doses first patient in phase 3 pivotal clinical study evaluating pharmacokinetics and pharmacodynamics of anaphylm™ (epinephrine) sublingual film

Warren, n.j., dec. 05, 2023 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (the “company” or “aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the first patient has been dosed in its initial phase 3 pivotal pharmacokinetic (pk) clinical study of anaphylm™ (epinephrine) sublingual film. anaphylm is the company's orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
AQST Ratings Summary
AQST Quant Ranking